JP7601957B2 - Recombinant collagen for skin soothing and repair and uses thereof - Google Patents
Recombinant collagen for skin soothing and repair and uses thereof Download PDFInfo
- Publication number
- JP7601957B2 JP7601957B2 JP2023108556A JP2023108556A JP7601957B2 JP 7601957 B2 JP7601957 B2 JP 7601957B2 JP 2023108556 A JP2023108556 A JP 2023108556A JP 2023108556 A JP2023108556 A JP 2023108556A JP 7601957 B2 JP7601957 B2 JP 7601957B2
- Authority
- JP
- Japan
- Prior art keywords
- soothing
- restorative
- composition
- parts
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000008186 Collagen Human genes 0.000 title claims description 77
- 108010035532 Collagen Proteins 0.000 title claims description 77
- 229920001436 collagen Polymers 0.000 title claims description 77
- 230000008439 repair process Effects 0.000 title claims description 19
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims description 64
- 229920002305 Schizophyllan Polymers 0.000 claims description 64
- 230000000694 effects Effects 0.000 claims description 64
- 238000000576 coating method Methods 0.000 claims description 58
- 239000011248 coating agent Substances 0.000 claims description 57
- 238000002360 preparation method Methods 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 30
- 238000000855 fermentation Methods 0.000 claims description 23
- 230000004151 fermentation Effects 0.000 claims description 23
- 235000011187 glycerol Nutrition 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 229940094541 polyglycerin-10 Drugs 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 15
- 230000005684 electric field Effects 0.000 claims description 14
- 230000003020 moisturizing effect Effects 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 241000222481 Schizophyllum commune Species 0.000 claims description 7
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims description 7
- 229940070765 laurate Drugs 0.000 claims description 7
- 239000003094 microcapsule Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004909 Moisturizer Substances 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 230000001333 moisturizer Effects 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- 229940049964 oleate Drugs 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229940014041 hyaluronate Drugs 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 claims description 2
- 229940044176 ceramide 3 Drugs 0.000 claims description 2
- 241000219781 Pueraria montana var. lobata Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 52
- 238000012360 testing method Methods 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 18
- 208000003251 Pruritus Diseases 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 13
- 230000003647 oxidation Effects 0.000 description 12
- 238000007254 oxidation reaction Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 244000046146 Pueraria lobata Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 229960001660 histamine phosphate Drugs 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000001187 Collagen Type III Human genes 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- -1 superoxide anion radicals Chemical class 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000009736 Collagen Type XI Human genes 0.000 description 1
- 108010034789 Collagen Type XI Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical group O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、スキンケアの技術分野に関し、具体的に、皮膚の鎮静・修復用の組換えコラーゲンおよびその使用に関する。 The present invention relates to the field of skin care, specifically to recombinant collagen and its uses for skin soothing and repair.
皮膚細胞内外の環境が変化すると、皮膚の防衛および修復機構が変化に適応できず、皮膚の損傷、および損傷の累積による老化状態を引き起こしている。検討によれば、ラジカルは、人体の老化を引き起こす重要な要素の1つであることが示されている。人体内に、様々なラジカル、たとえばスーパーオキシドアニオンラジカル、ヒドロキシルラジカル、DPPHラジカルなどが存在し、ラジカルは、細胞および組織の分解、代謝機能の低下を招来する恐れがある。正常な代謝以外、人体内のラジカルの濃度は、日照り、汚染、運動程度、精神状態などの要素にも影響されている。そのため、耐酸化成分を含有するスキンケア製品を用いて、多すぎるラジカルを除去し、体の退化を遅延し、皮膚の老化を抑制することができる。 When the environment inside and outside the skin cells changes, the skin's defense and repair mechanisms cannot adapt to the changes, causing skin damage and aging due to the accumulation of damage. Studies have shown that radicals are one of the important factors that cause aging in the human body. Various radicals, such as superoxide anion radicals, hydroxyl radicals, and DPPH radicals, exist in the human body, and radicals may cause cell and tissue decomposition and a decline in metabolic function. In addition to normal metabolism, the concentration of radicals in the human body is also affected by factors such as drought, pollution, exercise level, and mental state. Therefore, skin care products containing anti-oxidant ingredients can be used to remove excess radicals, delay body degeneration, and inhibit skin aging.
シゾフィランは、スエヒロタケからの天然由来のβ-D-グルカンであり、(1-3)-結合のβ-D-ピラン型グルコース残基の主鎖および(1-6)-結合のピラン型グルコース残基の側鎖からなり、耐酸化および耐放射の能力を持っている。シゾフィランは、細胞酸化酵素系の抑制や、酸化した遷移金属イオンの錯化誘導により、ラジカルの生成を抑制することができ、ラジカルの除去、遺伝子発現の調節、およびタンパク質の合成などの手段で耐放射の作用を果たし、放射により損傷された細胞のアポトーシス時間を延長し、脂質の過酸化を抑制することができる。 Schizophyllan is a naturally occurring β-D-glucan from Schizophyllum commune, which consists of a main chain of (1-3)-linked β-D-pyran type glucose residues and a side chain of (1-6)-linked pyran type glucose residues, and has the ability to resist oxidation and radiation. Schizophyllan can suppress the generation of radicals by inhibiting the cellular oxidative enzyme system and inducing the complexation of oxidized transition metal ions, and exerts a radiation resistance effect by means of radical scavenging, regulating gene expression, and protein synthesis, and can extend the apoptosis time of cells damaged by radiation and inhibit lipid peroxidation.
コラーゲンは、生体高分子であり、動物の結合組織における主成分であり、哺乳動物の体内の含有量が最も多く、分布が最も広い機能性タンパク質でもあり、タンパク質の総量の25~30%を占めている。コラーゲンは、良好な生体適合性、生体分解性および生体活性を有するため、食品、医薬、組織工学(Tissue engineering)などの分野において広く適用されている。コラーゲンは、I型コラーゲン分子、III型コラーゲン分子、IV型コラーゲン分子、XI型コラーゲン分子などを含み、皮膚に保湿し、潤い、細胞の増殖を促進し、細胞のバリアを補強させる作用を有している。 Collagen is a biopolymer and the main component of animal connective tissues. It is also the functional protein with the highest content and widest distribution in mammalian bodies, accounting for 25-30% of the total protein. Collagen has good biocompatibility, biodegradability and bioactivity, and is therefore widely used in the fields of food, medicine, tissue engineering and other fields. Collagen includes type I collagen molecules, type III collagen molecules, type IV collagen molecules, type XI collagen molecules, etc., and has the effects of moisturizing and hydrating the skin, promoting cell proliferation and reinforcing the cell barrier.
CN113057932Aは、皮膚のしわを改善するコラーゲンスキンケア製品が開示されている。この皮膚のしわを改善するコラーゲンスキンケア製品は、重量部で、活性植物5~15部、グリセリン10~15部、ブチレングリコール1~2部、活性添加物7~13部、コラーゲン5~10部および脱イオン水30~40部を原料として含み、粉砕、混合、発泡撹拌、二次混合、殺菌を経由し、コラーゲンの添加、最終混合により調製された。該発明は、調製時にスキンケア製品生産設備を採用することで、生産が改善され、収集に便利であり、最終に得られたスキンケア製品がコラーゲン活性、およびコラーゲンの生産を促進する活性を有し、加齢に伴って皮膚が老化してしわが現れてきたという問題を効果的に改善することができる。 CN113057932A discloses a collagen skin care product that improves skin wrinkles. This collagen skin care product that improves skin wrinkles contains, by weight, 5-15 parts of active plants, 10-15 parts of glycerin, 1-2 parts of butylene glycol, 7-13 parts of active additives, 5-10 parts of collagen, and 30-40 parts of deionized water as raw materials, and is prepared by grinding, mixing, foaming stirring, secondary mixing, sterilization, adding collagen, and final mixing. The invention adopts skin care product production equipment during preparation, which improves production and makes collection convenient, and the final skin care product has collagen activity and activity to promote collagen production, and can effectively improve the problem of wrinkles appearing due to skin aging with age.
CN102670477Aは、治療効果が良く、副作用がない、皮膚の欠陥を改善するコラーゲンスキンケア製品が開示されている。該スキンケア製品は、重量部で、10~30部の海藻(植物コラーゲン高含有)、10~30部のはちみつ、1~5部のビタミンEを含む。 CN102670477A discloses a collagen skin care product that has good therapeutic effects, no side effects, and improves skin defects. The skin care product contains, by weight, 10-30 parts of seaweed (high in plant collagen), 10-30 parts of honey, and 1-5 parts of vitamin E.
従って、耐酸化、抗老化、修復および保湿活性などの多重効果を備えるスキンケア製品
組成物を探索し、複数の角度から皮膚の損傷に対する修復を補強することについては、非常に有意義なものになっている。
Therefore, it has become very meaningful to explore skin care product compositions with multiple effects such as anti-oxidation, anti-aging, repair and moisturizing activity, and to reinforce the repair of skin damage from multiple angles.
従来技術の不足に対して、本発明は、組換えコラーゲンおよびその使用を提供し、特に皮膚の鎮静・修復用の組換えコラーゲンおよびその使用を提供することを目的とする。 In response to the deficiencies of the prior art, the present invention aims to provide recombinant collagen and uses thereof, in particular for soothing and repairing the skin, and uses thereof.
その目的を達成するために、本発明は、以下の技術案をを採用する。 To achieve this objective, the present invention employs the following technical solutions:
第1態様として、本発明は、皮膚の鎮静・修復用の組換えコラーゲンであって、前記皮膚の鎮静・修復用の組換えコラーゲンをコードするヌクレオチド配列は、SEQ ID NO:1で示される配列を含む皮膚の鎮静・修復用の組換えコラーゲンを提供する。 In a first aspect, the present invention provides a recombinant collagen for soothing and repairing skin, the nucleotide sequence encoding the recombinant collagen for soothing and repairing skin comprising the sequence shown in SEQ ID NO:1.
SEQ ID NO:1で示されるヌクレオチド配列は、以下の通りである。 The nucleotide sequence shown in SEQ ID NO:1 is as follows:
GGGCCTCAAGGTATTGCTGGACAGCGTGGTGTGGTCGGCCTGCCTGGTCAGAGAGGAGAGAGAGGCTTCCCTGGTCTTCCTGGCCCCTCTGGTGAACCTGGCAAACAAGGTCCCTCTGGAGCAAGTGGTGAACGTGGTCCCCCTGGTCCCATGGGCCCCCCTGGATTGGCTGGACCCCCTGGTGAATCTGGACGTGAGGGGGCTCCTGGTGCCGAAGGTTCCCCTGGACGAGACGGTTCTCCTGGCGCCAAGGGTGACCGTGGTGAGACCGGCCCCGCTGGACCCCCTGGTGCTCCTGGTGCTCCTGGTGCCCCTGGCCCCGTTGGCCCTGCTGGCAAGAGTGGTGATCGTGGTGAGACTGGTCCTGCTGGTCCCGCCGGAGAACGAGGTGGCCCTGGAGGACCTGGCCCTCAGGGTCCTCCTGGAAAGAATGGTGAAACTGGACCTCAGGGACCCCCAGGGCCTACTGGGCCTGGTGGTGACAAAGGAGACACAGGACCCCCTGGTCCACAAGGATTACAAGGCTTGCCTGGTACAGGTGGTCCTCCAGGAGAAAATGGAAAACCTGGGGAACCAGGTCCAAAGGGTGATGCCGGTGCACCTGGAGCTCCAGGAGGCAAGGGTGATGCTGGTGCCCCTGGTGAACGTGGACCTCCTGGATTGGCAGGGGCCCCAGGACTTAGAGGTGGAGCTGGTCCCCCTGGTCCCGAAGGAGGAAAGGGTGCTGCTGGTCCTCCTGGGCCACCTGGTGCTGCTGGTACTCCTGGTCTGCAAGGAATGCCTGGACCTGGTCCTTGCTGTGGTGGTTAA GGGCCTCAAGGTATTGCTGGACAGCGTGGTGTGGTCGGCCTGCCTGGTCAGAGAGGAGAGAGAGGCTTCCCTGGTCTTCCTGGCCCCTCTGGTGAACCTGG CAAACAAGGTCCCTCTGGAGCAAGTGGTGAACGTGGTCCCCCTGGTCCCATGGGCCCCCTGGATTGGCTGGACCCCCTGGTGAATCTGGACGTGAGGGGG CTCCTGGTGCCGAAGGTTCCCCTGGACGAGACGGTTCTCCTGGCGCCAAGGGTGACCGTGGTGAGACCGGCCCCGCTGGACCCCCTGGTGCTCCTGGTGCT CCTGGTGCCCCTGGCCCCGTTGGCCCTGCTGGCAAGAGTGGTGATCGTGGTGAGACTGGTCCTGCTGGTCCCGCCGGAGAACGAGGTGGCCCTGGAGGACCT GGCCCTCAGGGTCCTCCTGGAAAGAATGGTGAAAACTGGACCTCAGGGACCCCAGGGCCCTACTGGGCCTGGTGGTGACAAAGGAGACACAGGACCCCCTGG TCCACAAGGATTACAAGGCTTGCCTGGTACAGGTGGTCCTCCAGGAGAAATGGAAAACCTGGGGAACCAGGTCCAAAGGGTGATGCCGGTGGCACCTGGAGC TCCAGGAGGCAAGGGTGATGCTGGTGCCCCTGGTGAACGTGGACCTCCTGGATTGGCAGGGGCCCCAGGACTTAGAGGTGGAGCTGGTCCCCCTGGTCCCG AAGGAGGAAAGGGTGCTGCTGGTCCTCCTGGGCCACCTGGTGCTGCTGGTACTCCTGGTCTGCAAGGAATGCCTGGACCTGGTCCTTGCTGTGGTGGTTAA
本発明では、創造的に新規な組換えコラーゲン配列が発見される。前記皮膚の鎮静・修復用の組換えコラーゲンをコードするヌクレオチド配列は、SEQ ID NO:1で示される配列を含み、SEQ ID NO:1でコードされたアミノ酸配列は、I型コラーゲン950~1075位アミノ酸、III型コラーゲン594~729位および1193~1199位アミノ酸を含む。前記組換えコラーゲンは、保湿、皮膚のコラーゲンの補給、細胞増殖の促進、耐酸化、抗老化などの効果を有するとともに、良好な組織適合性、皮膚透過性および安全性を有する。 In the present invention, a creatively novel recombinant collagen sequence is discovered. The nucleotide sequence encoding the recombinant collagen for skin soothing and repair comprises the sequence shown in SEQ ID NO:1, and the amino acid sequence encoded by SEQ ID NO:1 comprises amino acids 950-1075 of type I collagen, and amino acids 594-729 and 1193-1199 of type III collagen. The recombinant collagen has effects such as moisturizing, replenishing collagen in the skin, promoting cell proliferation, anti-oxidation, and anti-aging, and also has good tissue compatibility, skin permeability, and safety.
第2態様として、本発明は、
第1態様に記載の皮膚の鎮静・修復用の組換えコラーゲンと、シゾフィランとを含む鎮静・修復効果を有する組成物を提供する。
In a second aspect, the present invention provides a method for producing a composition comprising:
The present invention provides a composition having a soothing and repairing effect, comprising the recombinant collagen for soothing and repairing skin according to the first aspect and schizophyllan.
本発明に係る鎮静・修復効果を有する組成物は、第1態様に記載の皮膚の鎮静・修復用の組換えコラーゲンと、シゾフィランとを含み、2種の成分を組み合わせて使用し、相俟って、保湿、耐酸化、細胞増殖の促進、さらに皮膚損傷の修復の向上などの点で相乗効果を有する。 The composition having a soothing and repairing effect according to the present invention contains the recombinant collagen for soothing and repairing the skin described in the first aspect and schizophyllan, and the two components are used in combination to have a synergistic effect in terms of moisturizing, oxidation resistance, promotion of cell proliferation, and improved repair of skin damage.
好ましくは、前記鎮静・修復効果を有する組成物は、質量部で、
0.01~0.5部の皮膚の鎮静・修復用の組換えコラーゲンおよび0.1~5部のシゾフィランを含む。
Preferably, the soothing and restorative composition comprises, in parts by weight:
It contains 0.01 to 0.5 parts of recombinant collagen for skin soothing and repair and 0.1 to 5 parts of schizophyllan.
前記皮膚鎮静・修復の組換えコラーゲンの質量部は、0.01部、0.1部、0.2部、0.3部、0.4部または0.5部などを選択することができる。 The mass parts of the skin soothing and repairing recombinant collagen can be selected from 0.01 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, etc.
前記シゾフィランの質量部は、0.1部、1部、2部、3部、4部または5部などを選択することができる。 The mass parts of schizophyllan can be selected from 0.1 parts, 1 parts, 2 parts, 3 parts, 4 parts, 5 parts, etc.
上記の各数値範囲内の具体的な点値はすべて選択可能であり、ここで説明を省略する。 All specific point values within each of the above numerical ranges can be selected, and so we will not explain them here.
本発明に係る鎮静・修復効果を有する組成物は、質量部で、0.01~0.5部の皮膚の鎮静・修復用の組換えコラーゲンおよび0.1~5部のシゾフィランを含む場合、両者を組み合わせて使用することで、皮膚損傷に対する修復効果がさらに優れる。 When the composition having a soothing and repairing effect according to the present invention contains, by mass, 0.01 to 0.5 parts of recombinant collagen for soothing and repairing the skin and 0.1 to 5 parts of schizophyllan, the use of both in combination provides an even more excellent repairing effect against skin damage.
好ましくは、前記鎮静・修復効果を有する組成物は、保湿剤をさらに含む。 Preferably, the composition having the soothing and restorative effect further contains a moisturizer.
好ましくは、前記保湿剤は、グリセリン、1,3-ブタンジオール、ヒアルロン酸ナトリウム、アセチルヒアルロン酸ナトリウム、加水分解ヒアルロン酸ナトリウムまたはセラミド3のいずれか1種または少なくとも2種の組合せを含む。前記少なくとも2種の組合せは、グリセリンと1,3-ブタンジオールの組合せ、1,3-ブタンジオールとヒアルロン酸ナトリウムの組合せまたはヒアルロン酸ナトリウムとアセチルヒアルロン酸ナトリウムの組合せなどを含み、他の任意の組合せ形態は、いずれも選択可能であり、ここで説明を省略する。 Preferably, the moisturizer includes one or a combination of at least two of glycerin, 1,3-butanediol, sodium hyaluronate, sodium acetylated hyaluronate, hydrolyzed sodium hyaluronate, or ceramide 3. The combination of at least two includes a combination of glycerin and 1,3-butanediol, a combination of 1,3-butanediol and sodium hyaluronate, or a combination of sodium hyaluronate and sodium acetylated hyaluronate, and any other combination form can be selected, and the description thereof will be omitted here.
好ましくは、前記保湿剤は、グリセリンである。 Preferably, the moisturizer is glycerin.
本発明に係る保湿剤がグリセリンを特定選択する場合、前記皮膚の鎮静・修復用の組換えコラーゲンとシゾフィランとの組合せは、さらに、グリセリンと組み合わせて使用することができ、保湿の点でより強い相乗効果を発揮する。 When the moisturizer of the present invention specifically selects glycerin, the combination of the recombinant collagen and schizophyllan for skin soothing and repair can be further used in combination with glycerin to exert a stronger synergistic effect in terms of moisturization.
好ましくは、前記鎮静・修復効果を有する組成物は、質量部で、
0.01~0.5部の第1態様に記載の皮膚の鎮静・修復用の組換えコラーゲン、0.1~5部のシゾフィランおよび5~50部のグリセリンを含む。
Preferably, the soothing and restorative composition comprises, in parts by weight:
It comprises 0.01 to 0.5 parts of the recombinant collagen for skin soothing and repair according to the first aspect, 0.1 to 5 parts of schizophyllan and 5 to 50 parts of glycerin.
前記皮膚の鎮静・修復用の組換えコラーゲンの質量部は、0.01部、0.1部、0.2部、0.3部、0.4部または0.5部などを選択することができる。 The mass parts of the recombinant collagen for skin soothing and repair can be selected from 0.01 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, etc.
前記シゾフィランの質量部は、0.1部、1部、2部、3部、4部または5部などを選択することができる。 The mass parts of schizophyllan can be selected from 0.1 parts, 1 parts, 2 parts, 3 parts, 4 parts, 5 parts, etc.
前記グリセリンの質量部は、5部、10部、15部、20部、25部、30部、35部、40部、45部または50部などを選択することができる。 The mass parts of glycerin can be selected from 5 parts, 10 parts, 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts, or 50 parts.
上記の各数値範囲内の具体的な点値はすべて選択可能であり、ここで説明を省略する。 All specific point values within each of the above numerical ranges can be selected, and so we will not explain them here.
好ましくは、前記シゾフィランの調製方法は、
葛根を含有する培地で、スエヒロタケを発酵培養させ、発酵培養液に対してSevag法でタンパク質を除去した後、エタノール溶液を添加して発酵培養液における多糖を沈殿させ、前記シゾフィランを調製したことを含む。
Preferably, the method for preparing schizophyllan comprises:
The method includes fermenting and culturing Schizophyllan in a medium containing kudzu root, removing proteins from the fermentation culture liquid by the Sevag method, and then adding an ethanol solution to precipitate polysaccharides in the fermentation culture liquid, thereby preparing the schizophyllan.
本発明に係るシゾフィランは、葛根を含有する培地でスエヒロタケを発酵させることにより調製されたものである。調製されたシゾフィランは、耐酸化、細胞修復、保湿及び免疫調節などの点で効果がより顕著である。そのため、培地に葛根を添加して調製されたシゾフィランは、前記鎮静・修復効果を有する組成物の調製に用いられる場合、前記組成物の耐酸化、修復および保湿作用をさらに補強させる。 The schizophyllan of the present invention is prepared by fermenting Schizophyllum commune in a medium containing kudzu root. The prepared schizophyllan has more significant effects in terms of oxidation resistance, cell repair, moisturizing, and immune regulation. Therefore, when schizophyllan prepared by adding kudzu root to a medium is used to prepare a composition having the above-mentioned sedative and repairing effects, it further reinforces the oxidation resistance, repair, and moisturizing effects of the composition.
第3態様として、本発明は、鎮静・修復効果を有する被覆体を提供する。前記鎮静・修復効果を有する被覆体は、
マイクロカプセル材と、前記マイクロカプセル材の内部に被覆された第2態様に記載の鎮静・修復効果を有する組成物と、を含む。
In a third aspect, the present invention provides a soothing and restorative coating, the soothing and restorative coating comprising:
The composition includes a microencapsulated material and the soothing and restorative composition according to the second aspect coated inside the microencapsulated material.
本発明に係る前記鎮静・修復効果を有する被覆体は、第2態様に記載の鎮静・修復効果を有する組成物の外部にマイクロカプセル材を被覆したものである。被覆の後、前記鎮静・修復作用を有する組成物は、浸透作用がより強く、皮膚組織に用いられる場合、発揮された保湿、耐酸化、鎮静・修復などの作用もさらに補強する。 The coating having a soothing and repairing effect according to the present invention is a coating of a microcapsule material on the outside of the composition having a soothing and repairing effect described in the second embodiment. After coating, the composition having a soothing and repairing effect has a stronger penetrating effect, and when used on skin tissue, it further reinforces the moisturizing, oxidation resistance, soothing and repairing effects that have already been exerted.
好ましくは、前記マイクロカプセル材の調製原料は、ポリグリセリル非イオン界面活性剤を含む。 Preferably, the raw material for preparing the microcapsule material contains a polyglyceryl nonionic surfactant.
好ましくは、前記ポリグリセリル非イオン界面活性剤は、ポリグリセリン-10ジイソステアリン酸エステル、ポリグリセリン-10ラウリン酸エステルまたはポリグリセリン-10オレイン酸エステルのいずれか1種または少なくとも2種の組合せを含む。前記少なくとも2種の組合せは、ポリグリセリン-10ジイソステアリン酸エステルとポリグリセリン-10ラウリン酸エステルとの組合せ、ポリグリセリン-10ラウリン酸エステルまたはポリグリセリン-10オレイン酸エステルの組合せまたはポリグリセリン-10ジイソステアリン酸エステルとポリグリセリン-10オレイン酸エステルとの組合せなどを含み、他の任意の組合せ形態は、いずれも選択可能であり、ここで説明を省略する。 Preferably, the polyglyceryl nonionic surfactant comprises one or a combination of at least two of polyglycerin-10 diisostearate, polyglycerin-10 laurate, or polyglycerin-10 oleate. The combination of at least two includes a combination of polyglycerin-10 diisostearate and polyglycerin-10 laurate, a combination of polyglycerin-10 laurate or polyglycerin-10 oleate, or a combination of polyglycerin-10 diisostearate and polyglycerin-10 oleate, and any other combination form can be selected, and a description thereof will be omitted here.
第4態様として、本発明は、第3態様に記載の鎮静・修復効果を有する被覆体の調製方法を提供する。前記調製方法は、
ポリグリセリル非イオン界面活性剤と、第2態様に記載の鎮静・修復効果を有する組成物を混合するステップ(1)と、
ステップ(1)で調製された混合物に対して被覆支援処理を行い、前記鎮静・修復効果を有する被覆体を調製し、前記被覆支援処理は高電圧パルス電界支援処理および/または超音波支援処理を含むステップ(2)と、を含む。
In a fourth aspect, the present invention provides a method for preparing a soothing and restorative coating according to the third aspect, said method comprising the steps of:
(1) mixing a polyglyceryl nonionic surfactant with the soothing and restorative composition according to the second aspect;
and step (2) of subjecting the mixture prepared in step (1) to a coating-assisted process to prepare the coating having the soothing and repairing effect, the coating-assisted process including a high-voltage pulsed electric field-assisted process and/or an ultrasonic-assisted process.
本発明に係る鎮静・修復効果を有する被覆体の調製方法は、有効成分とマイクロカプセル材を混合するだけで、被覆支援処理の作用下で前記被覆体を調製できる。本方法は、調製プロセスがシンプルであり、産業的拡大を容易にする。 The method for preparing a coating having a soothing and repairing effect according to the present invention can prepare the coating under the action of a coating-assisted treatment by simply mixing the active ingredient with the microcapsule material. This method has a simple preparation process, facilitating industrial expansion.
好ましくは、ステップ(2)における被覆支援処理は、高電圧パルス電界支援処理である。 Preferably, the coating-assisted process in step (2) is a high-voltage pulsed electric field-assisted process.
好ましくは、前記高電圧パルス電界支援処理は、電界強度が0.5~2kV/cmであり、パルス処理数が10~60個であり、材料の導電率が2000~6000μS/cmである。 Preferably, the high-voltage pulse electric field assisted treatment has an electric field strength of 0.5 to 2 kV/cm, a number of pulse treatments of 10 to 60, and a material conductivity of 2000 to 6000 μS/cm.
前記0.5~2kV/cmのうちの具体的な数値は、0.5kV/cm、0.7kV/cm、0.9kV/cm、1.1kV/cm、1.3kV/cm、1.5kV/cm、1.7kV/cm、1.9kV/cmまたは2kV/cmなどを選択することができる。 Specific values from the range of 0.5 to 2 kV/cm can be selected as 0.5 kV/cm, 0.7 kV/cm, 0.9 kV/cm, 1.1 kV/cm, 1.3 kV/cm, 1.5 kV/cm, 1.7 kV/cm, 1.9 kV/cm, or 2 kV/cm, etc.
前記10~60個のうちの具体的な数値は、10個、20個、30個、40個、50個または60個などを選択することができる。 Specific values from the 10 to 60 range can be selected as 10, 20, 30, 40, 50, or 60, etc.
前記2000~6000μS/cmのうちの具体的な数値は、2000μS/cm、3000μS/cm、4000μS/cm、5000μS/cmまたは6000μS/cmなどを選択することができる。 Specific values within the range of 2000 to 6000 μS/cm can be selected as 2000 μS/cm, 3000 μS/cm, 4000 μS/cm, 5000 μS/cm, or 6000 μS/cm, etc.
上記の各数値範囲内の具体的な点値はすべて選択可能であり、ここで説明を省略する。 All specific point values within each of the above numerical ranges can be selected, and so we will not explain them here.
第5態様として、本発明は、第1態様に記載の組換えコラーゲン、第2態様に記載の鎮静・修復効果を有する組成物または第3態様に記載の鎮静・修復効果を有する被覆体のスキンケア製品の調製における使用を提供する。 In a fifth aspect, the present invention provides the use of the recombinant collagen according to the first aspect, the composition having a soothing and restorative effect according to the second aspect, or the coating having a soothing and restorative effect according to the third aspect in the preparation of a skin care product.
従来技術に対して、本発明は、以下の有益な効果を有する。 Compared to conventional technology, the present invention has the following beneficial effects:
1、本発明では、前記皮膚の鎮静・修復用の組換えコラーゲンをコードするヌクレオチド配列は、SEQ ID NO:1で示される配列を含み、SEQ ID NO:1でコードされたアミノ酸配列は、I型コラーゲン950~1075位アミノ酸、III型コラーゲン594~729位および1193~1199位アミノ酸を含む。前記組換えコラーゲンは、保湿、皮膚のコラーゲンの補給、細胞増殖の促進、耐酸化、抗老化などの効果を有するとともに、良好な組織適合性、皮膚透過性および安全性を有する。 1. In the present invention, the nucleotide sequence encoding the recombinant collagen for skin soothing and repairing comprises the sequence shown in SEQ ID NO:1, and the amino acid sequence encoded by SEQ ID NO:1 comprises amino acids 950-1075 of type I collagen, and amino acids 594-729 and 1193-1199 of type III collagen. The recombinant collagen has effects such as moisturizing, supplementing collagen in the skin, promoting cell proliferation, anti-oxidation, and anti-aging, and also has good tissue compatibility, skin permeability, and safety.
2、本発明に係る鎮静・修復効果を有する組成物は、第1態様に記載の皮膚の鎮静・修復用の組換えコラーゲンとシゾフィランとを含み、2種の成分を組み合わせて使用し、相俟って、保湿、耐酸化、細胞増殖の促進、さらに皮膚損傷に対する修復などの点で相乗作用を有する。 2. The composition having a soothing and repairing effect according to the present invention contains the recombinant collagen for soothing and repairing the skin described in the first aspect and schizophyllan, and the two components are used in combination to have a synergistic effect in terms of moisturizing, oxidation resistance, promotion of cell proliferation, and repair of skin damage.
3、本発明に係る前記鎮静・修復効果を有する被覆体は、第2態様に記載の鎮静・修復効果を有する組成物の外部にマイクロカプセル材を被覆したものである。被覆の後、前記鎮静・修復作用を有する組成物は、浸透作用がより強く、皮膚組織に用いられる場合、発揮された保湿、耐酸化、鎮静・修復などの作用もさらに補強する。 3. The coating having a soothing and repairing effect according to the present invention is a coating of a microcapsule material on the outside of the composition having a soothing and repairing effect described in the second aspect. After coating, the composition having a soothing and repairing effect has a stronger penetrating effect, and when used on skin tissue, it further reinforces the moisturizing, oxidation resistance, soothing and repairing effects that have already been exerted.
4、本発明に係る鎮静・修復効果を有する被覆体の調製方法は、有効成分とマイクロカプセル材を混合するだけで、被覆支援処理の作用下で前記被覆体を調製できる。本方法は、調製プロセスがシンプルであり、産業的拡大を容易にする。 4. The method for preparing a coating having a soothing and restorative effect according to the present invention can prepare the coating under the action of a coating-assisted treatment by simply mixing the active ingredient with the microcapsule material. This method has a simple preparation process, facilitating industrial expansion.
以下、具体的な実施形態によって、さらに本発明の技術案を説明する。当業者であれば、かかる実施例が本発明を理解するためのものに過ぎず、本発明を具体に制限するものと見なすべきではないということを理解すべきである。 The technical solution of the present invention will be further described below by using specific embodiments. Those skilled in the art should understand that such examples are merely for understanding the present invention and should not be regarded as specifically limiting the present invention.
本発明では、実施過程、条件、試薬、試験方法などは、以下の意図的に言及されるもの以外、すべてこの分野の普遍的知識、および公知常識であり、特に限定されたものがない。各々の実施例における具体的な条件を明記していない試験方法については、通常は、慣用条件またはメーカーから推薦された条件に応じたものである。 In the present invention, the implementation process, conditions, reagents, test methods, etc., are all common knowledge and common general knowledge in this field, except for those intentionally mentioned below, and there are no particular limitations. Test methods for which specific conditions are not specified in each example are usually based on conventional conditions or conditions recommended by the manufacturer.
特に断らない限り、本明細書に用いられるすべての専門用語および科学用語は、いずれも本発明が属する分野の当業者にとって通常理解している意味と同じ意味を有する。しかし、矛盾があれば、定義を含む本発明に準じする。 Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. However, in case of conflict, the present invention, including definitions, shall control.
下記試験におけるpET-28a(+)ベクターは、MACKLINから購入されている。スエヒロタケは、広東省微生物研究所から購入されたスエヒロタケGIM 5.43菌株である。BL21(DE3)化学的コンピテント細胞は、MERCKから購入された、型番CMC0014-4X40ULのものである。 The pET-28a(+) vector in the following studies was purchased from MACKLIN. Schizophyllum commune is Schizophyllum commune GIM 5.43 strain purchased from Guangdong Provincial Institute of Microbiology. BL21(DE3) chemically competent cells were purchased from MERCK, model number CMC0014-4X40UL.
[調製例1]
本調製例は、皮膚の鎮静・修復用の組換えコラーゲン凍結乾燥粉末を提供する。前記皮膚の鎮静・修復用の組換えコラーゲン凍結乾燥粉末の調製方法は、以下のステップを含む。
[Preparation Example 1]
This preparation example provides a recombinant collagen freeze-dried powder for skin soothing and repair. The preparation method of the recombinant collagen freeze-dried powder for skin soothing and repair includes the following steps:
(1)組換えプラスミドの構築:上述したSEQ ID NO:1で示されるヌクレオチド配列に応じて、発現担体の大腸菌宿主に適用するpET-28a(+)ベクターを選択し、シークエンシング会社に送って合成して、組換えコラーゲン発現ベクターpET-28a-1を調製した。 (1) Construction of recombinant plasmid: According to the nucleotide sequence shown in SEQ ID NO: 1 above, the pET-28a(+) vector to be applied to the E. coli host as the expression carrier was selected, and sent to a sequencing company for synthesis to prepare the recombinant collagen expression vector pET-28a-1.
(2)組換え発酵菌株の構築:pET-28a-1発現ベクターを、化学変換法により大腸菌(BL21(DE3))コンピテント細胞に形質転換した。アガロースゲル電気泳動により、形質転換後の平板コロニーの陽性クローン単体を選別し、選別された陽性クローン単体を2mLのLB培地に転移接種し、37℃、200rpmで12h培養した。培養後の菌液を、体積分率50%のグリセリンで1倍希釈し、凍結保存チューブに分注し、-80℃の条件下で凍結保存し、組換えコラーゲン発酵菌株を調製した。 (2) Construction of recombinant fermentation strain: The pET-28a-1 expression vector was transformed into E. coli (BL21(DE3)) competent cells by chemical conversion. After transformation, positive single clones from the plate colonies were selected by agarose gel electrophoresis, and the selected positive single clones were transferred and inoculated into 2 mL of LB medium and cultured at 37°C and 200 rpm for 12 hours. After culture, the bacterial solution was diluted 1-fold with 50% volumetric glycerin, dispensed into cryopreservation tubes, and cryopreserved at -80°C to prepare a recombinant collagen fermentation strain.
(3)組換え発酵菌株の発酵培養:10μLのLB組換えコラーゲン発酵菌液を固体LBプレートに塗布し、37℃のインキュベーターで12h培養した後、モノクローンを選別して、50mLの50μg/mLカナマイシン含有量を含有するLB液体培地に接種し、シェーカーに置き、37℃、200rpmで14h培養した。そして、1:100の割合で200mLの50μg/mLカナマイシン含有量を含有するLB液体培地に接種し、37℃で、菌液OD=0.6までに培養した後、IPTGを添加し、最終濃度が1mMになって、継続して4h培養した。その後、4℃、4000rpmで、15min遠心して菌体を収集した。 (3) Fermentation culture of recombinant fermentation strain: 10 μL of LB recombinant collagen fermentation culture was applied to a solid LB plate and cultured in an incubator at 37°C for 12 hours, after which a monoclone was selected and inoculated into 50 mL of LB liquid medium containing 50 μg/mL kanamycin, placed on a shaker and cultured at 37°C and 200 rpm for 14 hours. Then, it was inoculated into 200 mL of LB liquid medium containing 50 μg/mL kanamycin at a ratio of 1:100, cultured at 37°C until the culture OD was 0.6, IPTG was added to the final concentration of 1 mM, and cultured for 4 hours. Then, the cells were collected by centrifugation at 4°C and 4000 rpm for 15 minutes.
(4)組換えコラーゲンの精製:菌体を超音波粉砕した後、遠心し、沈殿をTritonX-100洗浄液で洗浄し、再度遠心して上澄みを除去し、沈殿に6Mの塩酸グアニジンを添加し、pHを8に調節し、沈澱を十分に溶解させた後、溶解液にニッケルアフィニティークロマトグラフィー樹脂を通じさせ、20mM、50mM、100mM、200mM、500mMの濃度勾配のイミダゾール溶液を使用して順次に溶出した。溶出液をタンパク質濃縮カラムで濃縮した後、濃縮液を収集して1晩透析した(透析袋、RC膜、14KD、扁平幅44mm(生工F600112))。その後、BCAキットでタンパク質の濃度を検出し、5mgのタンパク質当たりに体積濃度5%のマンニトール水溶液を0.5mL添加する割合でマンニトール水溶液と均一に混合した。その後、凍結乾燥機を用いて
-40℃で10min予め凍結し、最後に-35℃で凍結乾燥して、組換えコラーゲン凍結乾燥粉末を調製した。
(4) Purification of recombinant collagen: The bacterial cells were ultrasonically crushed, centrifuged, the precipitate was washed with TritonX-100 washing solution, and centrifuged again to remove the supernatant. 6M guanidine hydrochloride was added to the precipitate, the pH was adjusted to 8, and the precipitate was fully dissolved. The solution was then passed through a nickel affinity chromatography resin and eluted sequentially using imidazole solutions with a concentration gradient of 20mM, 50mM, 100mM, 200mM, and 500mM. The eluate was concentrated using a protein concentration column, and the concentrate was collected and dialyzed overnight (dialysis bag, RC membrane, 14KD, flat width 44mm (Seiko F600112)). The protein concentration was then detected using a BCA kit, and the mixture was uniformly mixed with an aqueous mannitol solution at a ratio of 0.5mL of a 5% volumetric concentration aqueous mannitol solution per 5mg of protein. Thereafter, the mixture was pre-frozen at −40° C. for 10 min using a freeze dryer, and finally freeze-dried at −35° C. to prepare a freeze-dried powder of recombinant collagen.
[調製例2]
本調製例は、シゾフィランを提供する。前記シゾフィランの調製方法は、以下の通りである。
[Preparation Example 2]
This preparation example provides schizophyllan. The method for preparing the schizophyllan is as follows.
(1)スエヒロタケ発酵生成物の調製:スエヒロタケを、5%の細菌接種量で発酵培地に接種し、28℃、160rpmの条件下で発酵した。120h発酵した後、発酵生成物を遠心処理し、菌体および葛根粉末を除去して発酵生成物を得た。発酵培地の成分は、0.6%の葛根粉末、0.3%の酵母エキス、0.05%の硫酸マグネシウム、0.1%のリン酸二水素カリウム、3%のグルコースおよび残量の水である。 (1) Preparation of Schizophyllum commune fermentation product: Schizophyllum commune was inoculated into the fermentation medium with a bacterial inoculum amount of 5%, and fermented under the conditions of 28°C and 160 rpm. After fermentation for 120 h, the fermentation product was centrifuged to remove the fungus body and kudzu root powder to obtain the fermentation product. The components of the fermentation medium were 0.6% kudzu root powder, 0.3% yeast extract, 0.05% magnesium sulfate, 0.1% potassium dihydrogen phosphate, 3% glucose, and the remaining amount was water.
(2)シゾフィランの調製:発酵生成物に同体積の蒸留水を添加して希釈した。希釈した後、体積分率0.5%の活性炭を添加し、80℃の水バス処理で40min脱色させ、遠心し、濾液を400メッシュ篩にかけて活性炭を除去し、澄み透明の発酵液を得た。発酵液は、Sevag法により、タンパク質を5回溶出した。その後、3倍体積の95%エタノールで発酵液における多糖を沈殿させた。洗浄した後、蒸留水を添加して再溶解し、流水および蒸留水中に24h透析した。透析液を濃縮させ、凍結乾燥し、前記シゾフィランを調製した。 (2) Preparation of schizophyllan: The fermentation product was diluted by adding an equal volume of distilled water. After dilution, 0.5% volume fraction of activated carbon was added, and the mixture was decolorized in a water bath at 80°C for 40 minutes, centrifuged, and the filtrate was sieved through a 400-mesh sieve to remove the activated carbon, yielding a clear fermentation liquid. Proteins were eluted from the fermentation liquid five times using the Sevag method. Polysaccharides in the fermentation liquid were then precipitated with three volumes of 95% ethanol. After washing, distilled water was added to redissolve the product, and the mixture was dialyzed against running water and distilled water for 24 hours. The dialyzed liquid was concentrated and freeze-dried to prepare the schizophyllan.
[調製例3]
本調製例は、シゾフィランを提供する。前記シゾフィランの調製方法は、発酵培地には葛根粉末が含まれない点だけで調製例2と異なり、他の操作はいずれも調製例2と同様である。
[Preparation Example 3]
This preparation example provides schizophyllan. The preparation method of schizophyllan is different from that of Preparation Example 2 only in that the fermentation medium does not contain pueraria root powder, and the other operations are all the same as those of Preparation Example 2.
[実施例1]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、以下の通りである。
[Example 1]
This example provides a coating with soothing and restorative effects. The method for preparing said coating is as follows:
(1)1部のポリグリセリン-10ジイソステアリン酸エステル、0.5部のポリグリセリン-10ラウリン酸エステル、0.2部の調製例1で調製された組換えコラーゲン、0.3部の調製例2で調製されたシゾフィランおよび15部のグリセリンを混合し、100部になるまで水を添加した。 (1) 1 part of polyglycerin-10 diisostearate, 0.5 parts of polyglycerin-10 laurate, 0.2 parts of the recombinant collagen prepared in Preparation Example 1, 0.3 parts of the schizophyllan prepared in Preparation Example 2, and 15 parts of glycerin were mixed and water was added until the total volume reached 100 parts.
(2)混合溶液に対して高電圧パルス電界支援処理を行った。パラメータとしては、電界強度が0.5kV/cmであり、パルス処理数が10個であり、材料の導電率が2000μS/cmである。処理の後、前記鎮静・修復効果を有する被覆体を得た。 (2) The mixed solution was subjected to high-voltage pulse electric field assisted treatment. The parameters were an electric field strength of 0.5 kV/cm, the number of pulse treatments was 10, and the material conductivity was 2000 μS/cm. After the treatment, a coating having the above-mentioned calming and repairing effects was obtained.
[実施例2]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、以下の通りである。
[Example 2]
This example provides a coating with soothing and restorative effects. The method for preparing said coating is as follows:
(1)1部のポリグリセリン-10ジイソステアリン酸エステル、0.5部のポリグリセリン-10ラウリン酸エステル、0.01部の調製例1で調製された組換えコラーゲン、5部の調製例2で調製されたシゾフィランおよび50部のグリセリンを混合し、100部になるまで水を添加した。 (1) 1 part of polyglycerin-10 diisostearate, 0.5 parts of polyglycerin-10 laurate, 0.01 parts of recombinant collagen prepared in Preparation Example 1, 5 parts of schizophyllan prepared in Preparation Example 2, and 50 parts of glycerin were mixed and water was added until the total volume reached 100 parts.
(2)混合溶液に対して高電圧パルス電界支援処理を行った。パラメータとしては、電界強度が0.5kV/cmであり、パルス処理数が20個であり、材料の導電率が600
0μS/cmである。処理の後、前記鎮静・修復効果を有する被覆体を得た。
(2) The mixed solution was subjected to high-voltage pulse electric field assisted treatment. The parameters were electric field strength of 0.5 kV/cm, the number of pulse treatments was 20, and the conductivity of the material was 600.
After the treatment, a coating having the above-mentioned soothing and repairing effect was obtained.
[実施例3]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、以下の通りである。
[Example 3]
This example provides a coating with soothing and restorative effects. The method for preparing said coating is as follows:
(1)1部のポリグリセリン-10ジイソステアリン酸エステル、0.5部のポリグリセリン-10ラウリン酸エステル、0.5部の調製例1で調製された組換えコラーゲン、0.1部の調製例2で調製されたシゾフィランおよび5部のグリセリンを混合し、100部になるまで水を添加した。 (1) 1 part of polyglycerin-10 diisostearate, 0.5 parts of polyglycerin-10 laurate, 0.5 parts of recombinant collagen prepared in Preparation Example 1, 0.1 parts of schizophyllan prepared in Preparation Example 2, and 5 parts of glycerin were mixed and water was added until the total volume reached 100 parts.
(2)混合溶液に対して高電圧パルス電界支援処理を行った。パラメータとしては、電界強度が2kV/cmであり、パルス処理数が60個であり、材料の導電率が2000μS/cmであり、処理の後、前記鎮静・修復効果を有する被覆体を得た。 (2) A high-voltage pulsed electric field assisted treatment was performed on the mixed solution. The parameters were an electric field strength of 2 kV/cm, the number of pulse treatments was 60, and the material conductivity was 2000 μS/cm. After the treatment, a coating having the above-mentioned calming and repairing effects was obtained.
[実施例4]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、調製原料にはグリセリンが含まれず、グリセリンの質量部を割合で組換えコラーゲンおよびシゾフィランに割り当てる点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Example 4]
This embodiment provides a coating having soothing and restorative effects. The preparation method of the coating is different from that of Example 1 only in that the raw materials do not contain glycerin, and the mass parts of glycerin are allocated to recombinant collagen and schizophyllan in a proportion, but the other operations are all the same as those of Example 1.
[実施例5]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、調製例2で調製されたシゾフィランを調製例3で調製されたシゾフィランに置き換える点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Example 5]
This example provides a coating having soothing and restorative effects. The preparation method of the coating is different from that of Example 1 only in that the schizophyllan prepared in Preparation Example 2 is replaced with the schizophyllan prepared in Preparation Example 3, and the other operations are all the same as those of Example 1.
[実施例6]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、0.2部の調製例1で調製された組換えコラーゲンおよび0.3部の調製例2で調製されたシゾフィランを、0.5部の組換えコラーゲンとシゾフィランとの混合物(混合物における組換えコラーゲンとシゾフィランの割合が0.01:5.1である)に置き換える点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Example 6]
This example provides a coating with soothing and repairing effects, the preparation method of said coating is different from that of Example 1 only in that 0.2 parts of the recombinant collagen prepared in Preparation Example 1 and 0.3 parts of the schizophyllan prepared in Preparation Example 2 are replaced with 0.5 parts of a mixture of recombinant collagen and schizophyllan (the ratio of recombinant collagen to schizophyllan in the mixture is 0.01:5.1), and all other operations are the same as those of Example 1.
[実施例7]
本実施例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、0.2部の調製例1で調製された組換えコラーゲンおよび0.3部の調製例2で調製されたシゾフィランを、0.5部の組換えコラーゲンとシゾフィランとの混合物(混合物における組換えコラーゲンとシゾフィランの割合が0.6:0.05である)に置き換える点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Example 7]
This example provides a coating with soothing and repairing effects, the preparation method of said coating is different from that of Example 1 only in that 0.2 parts of the recombinant collagen prepared in Preparation Example 1 and 0.3 parts of the schizophyllan prepared in Preparation Example 2 are replaced with 0.5 parts of a mixture of recombinant collagen and schizophyllan (the ratio of recombinant collagen to schizophyllan in the mixture is 0.6:0.05), and all other operations are the same as those of Example 1.
[比較例1]
本比較例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、調製原料には組換えコラーゲンが含まれず、組換えコラーゲンの質量部をシゾフィランに割り当てる点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Comparative Example 1]
This comparative example provides a coating having soothing and restorative effects. The preparation method of the coating is different from that of Example 1 only in that the raw materials do not contain recombinant collagen and the mass part of recombinant collagen is allocated to schizophyllan, but the other operations are all the same as those of Example 1.
[比較例2]
本比較例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、調製原料にはシゾフィランが含まれず、シゾフィランの質量部を組換えコラーゲンに割り当てる点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Comparative Example 2]
This comparative example provides a coating having soothing and repairing effects. The preparation method of the coating is different from that of Example 1 only in that the preparation raw material does not contain schizophyllan, and the mass part of schizophyllan is allocated to recombinant collagen, but the other operations are all the same as those of Example 1.
[比較例3]
本比較例は、鎮静・修復効果を有する被覆体を提供する。前記被覆体の調製方法は、調製原料には、シゾフィランおよび組換えコラーゲンが含まれず、シゾフィランおよび組換えコラーゲンの質量部をグリセリンに割り当てる点だけで実施例1と異なり、他の操作はいずれも実施例1と同様である。
[Comparative Example 3]
This comparative example provides a coating having a soothing and restorative effect. The preparation method of the coating is different from that of Example 1 only in that the preparation raw materials do not contain schizophyllan and recombinant collagen, and the parts by mass of schizophyllan and recombinant collagen are allocated to glycerin, but the other operations are all the same as those of Example 1.
[試験例1]
本試験例は、各々の実施例または比較例の鎮静・修復効果を有する被覆体の耐酸化作用について評価した。具体的な評価方法は、以下の通りである。
[Test Example 1]
In this test example, the oxidation resistance of the coating having the soothing and repairing effect of each of the Examples and Comparative Examples was evaluated. The specific evaluation method was as follows.
DPPHの消去効率を用いて実施例および比較例の耐酸化性能について評価した。具体的な評価方法は、以下の通りである。0.5gの被覆体をそれぞれ4mLのDPPH(100μM、99wt%のエタノール中で)溶液に浸漬し(対照群としてDPPHだけ含有する溶液を用い)、暗所で60minインキュベートした。そして、紫外-可視分光光度計で混合溶液の517nmにおける吸光度値を測定した。DPPH消去率=(対照群の吸光度-試験群の吸光度)/対照群の吸光度×100%という式で算出し、その結果を表1に示す。 The oxidation resistance of the examples and comparative examples was evaluated using the DPPH elimination efficiency. The specific evaluation method is as follows. 0.5 g of the coated body was immersed in 4 mL of DPPH (100 μM, in 99 wt % ethanol) solution (a solution containing only DPPH was used as the control group) and incubated in the dark for 60 min. The absorbance value of the mixed solution at 517 nm was then measured using a UV-Vis spectrophotometer. The DPPH elimination rate was calculated using the formula: DPPH elimination rate = (absorbance of control group - absorbance of test group) / absorbance of control group x 100%, and the results are shown in Table 1.
表1のデータから分かるように、比較例1および比較例2は、実施例1に比較すると、調製原料にはそれぞれ組換えコラーゲンおよびシゾフィランの1種を欠いて、そのDPPH消去率が実施例1よりも低いことから、シゾフィランおよび組換えコラーゲンの2種の成分が相俟って、DPPHを消去する点で、予想外の相乗効果を有することが判明した。実施例5は、実施例1に比較すると、発酵培地には葛根粉末が含まれ、そのDPPHの消去率が実施例1よりも低いことから、葛根粉末の添加によりシゾフィランの生成物の耐酸化性能を補強させることが判明した。実施例6および実施例7は、実施例1に比較すると、組換えコラーゲンとシゾフィランの質量部の割合が(0.01~0.5):(0.1~5)の範囲ではなく、そのDPPH消去率が実施例1よりも低いことから、組換えコラー
ゲンとシゾフィランの質量部の割合が(0.01~0.5):(0.1~5)の範囲である場合、この2種の成分を組み合わせて使用し、耐酸化性能がより強くなることが判明した。
As can be seen from the data in Table 1, in Comparative Example 1 and Comparative Example 2, compared with Example 1, the preparation raw materials lack one of recombinant collagen and schizophyllan, respectively, and the DPPH elimination rate is lower than that of Example 1, so it was found that the two components, schizophyllan and recombinant collagen, work together to have an unexpected synergistic effect in elimination of DPPH. In Example 5, compared with Example 1, the fermentation medium contains kudzu root powder, and the DPPH elimination rate is lower than that of Example 1, so it was found that the addition of kudzu root powder reinforces the oxidation resistance of the schizophyllan product. In comparison with Example 1, in Examples 6 and 7, the ratio of mass parts of recombinant collagen to schizophyllan is not within the range of (0.01-0.5):(0.1-5), and the DPPH elimination rate is lower than that of Example 1. This indicates that when the ratio of mass parts of recombinant collagen to schizophyllan is within the range of (0.01-0.5):(0.1-5), the oxidation resistance performance is stronger when these two components are used in combination.
[試験例2]
本試験例は、各々の実施例または比較例の鎮静・修復効果を有する被覆体の保湿作用について評価した。具体的な評価方法は、以下の通りである。
[Test Example 2]
In this test example, the moisturizing effect of the covering having soothing and repairing effects of each of the Examples and Comparative Examples was evaluated. The specific evaluation method was as follows.
皮膚が健康な18~40歳のボランティアを100人選択し、男女比が半分づつであり、ランダムに10群に分けており、実施例および比較例に係る鎮静・修復効果を有する被覆体を用いた。ボランティアがアームを洗浄した後、2mg/cmの使用量でアームの内側における直径2cmの試験領域に均一に塗布し、1日当たり1回、30日間連続して使用した。皮膚試験装置(MC750、ドイツCK)によってボランティアの使用前および使用後の皮膚含水量を測定した。 One hundred volunteers with healthy skin aged 18-40 years were selected, half of whom were male and half were randomly divided into 10 groups, and the coverings having soothing and repairing effects according to the examples and comparative examples were used. After the volunteers washed their arms, they evenly applied the coverings to a test area of 2 cm in diameter on the inside of their arms at a dose of 2 mg/cm, and used them once a day for 30 consecutive days. The skin moisture content of the volunteers was measured before and after use using a skin test device (MC750, CK, Germany).
使用前、および30日間連続して使用した後、それぞれ各被験者の皮膚含水量を測定し、データ当たり3回測定し、各群の平均値を算出し、皮膚含水量の変化率=(30日間使用後の皮膚含水量-使用前の皮膚含水量)/使用前の皮膚含水量×100%という式に従って皮膚含水量の変化率を算出し、測定結果を表2に示す。 The skin moisture content of each subject was measured before use and after 30 days of continuous use, with each data point measured three times, and the average value for each group was calculated. The rate of change in skin moisture content was calculated according to the formula: rate of change in skin moisture content = (skin moisture content after 30 days of use - skin moisture content before use) / skin moisture content before use x 100%, and the measurement results are shown in Table 2.
表2のデータから分かるように、比較例1および比較例2は、実施例1に比較すると、調製原料にはそれぞれ組換えコラーゲンおよびシゾフィランの一種を欠いて、その皮膚含水量の変化率が実施例1よりも低いことから、シゾフィランおよび組換えコラーゲンの2種の成分が相俟って、前記被覆体の保湿作用が補強可能となることが判明した。実施例4および比較例3は、実施例1に比較すると、前記鎮静・修復効果を有する被覆体の調製原料にはそれぞれグリセリンまたは組換えコラーゲンおよびシゾフィランの組合せを欠いて、その皮膚含水量の変化率がいずれも実施例1よりも低いことから、グリセリン、組換え
コラーゲンおよびシゾフィランの三つものを組み合わせて使用し、相俟って、皮膚保湿作用を向上させる点で予想外の相乗効果を有することが判明した。
As can be seen from the data in Table 2, in Comparative Example 1 and Comparative Example 2, the preparation raw materials lack recombinant collagen and one type of schizophyllan, respectively, compared with Example 1, and the change rate of the skin moisture content is lower than that of Example 1, so it was found that the two components of schizophyllan and recombinant collagen work together to reinforce the moisturizing effect of the cover. In Example 4 and Comparative Example 3, the preparation raw materials of the cover having the soothing and repairing effect lack glycerin or a combination of recombinant collagen and schizophyllan, respectively, compared with Example 1, and the change rate of the skin moisture content is both lower than that of Example 1, so it was found that the combination of glycerin, recombinant collagen, and schizophyllan has an unexpected synergistic effect in improving the moisturizing effect of the skin.
[試験例3]
本試験例は、調製例1の組換えコラーゲン、各々の実施例または比較例の鎮静・修復効果を有する被覆体の細胞増殖効果について評価した。具体的な評価方法は、以下の通りである。
[Test Example 3]
In this test example, the cell proliferation effect of the recombinant collagen of Preparation Example 1 and the coatings having soothing and repairing effects of the Examples and Comparative Examples was evaluated. The specific evaluation method was as follows.
成長状態が良好なHaCaT細胞(ヒト不死化角化細胞)を取り、96ウェルプレートに播いて17h培養した後、無血清基本培地へ交換し、7h培養した後、旧い培地を捨てて、1%の組換えコラーゲン水溶液、または各実施例または比較例で調製された被覆体溶液(被覆体の培地における濃度が2μg/mLである)を含有する培地に添加した。ブランクは、培地には被覆体を含まない以外、試験群と一致した。48h培養した後、CCK8法により、細胞生存率を検出し(630nmを基準波長として、波長450nmで吸光度値を測定し)、データ当たり3回測定し、各群の平均値を算出した。相対細胞増殖率=(試験群の吸光度-ブランクの吸光度)/ブランクの吸光度×100%という式に従って相対細胞増殖率を算出した。 HaCaT cells (human immortalized keratinocytes) in good growth condition were taken, seeded on a 96-well plate, and cultured for 17 hours, then replaced with serum-free basic medium. After 7 hours of culture, the old medium was discarded and a medium containing 1% recombinant collagen aqueous solution or the coated body solution prepared in each Example or Comparative Example (the coated body concentration in the medium was 2 μg/mL) was added. The blank was the same as the test group except that the medium did not contain the coated body. After 48 hours of culture, the cell viability was detected by the CCK8 method (630 nm was used as the reference wavelength, and the absorbance value was measured at a wavelength of 450 nm), and measurements were made three times per data point, and the average value of each group was calculated. The relative cell proliferation rate was calculated according to the formula: relative cell proliferation rate = (absorbance of test group - absorbance of blank) / blank absorbance x 100%.
表3のデータから分かるように、調製例1の組換えコラーゲンは、優れた細胞増殖促進効果を有する。また、比較例1および比較例2は、実施例1に比較すると、調製原料にはそれぞれ組換えコラーゲンおよびシゾフィランの1種を欠いて、その相対細胞増殖率が実施例1よりも低いことから、シゾフィランおよび組換えコラーゲンの2種の成分が相俟って、細胞増殖の促進の点で予想外の相乗効果を有することが判明した。実施例5は、実施例1に比較すると、発酵培地には葛根粉末が含まれ、その相対細胞増殖率が実施例1よりも低いので、葛根粉末の添加により、シゾフィランの細胞増殖の促進能力を補強させることが判明した。 As can be seen from the data in Table 3, the recombinant collagen of Preparation Example 1 has an excellent cell proliferation promoting effect. In addition, in Comparative Examples 1 and 2, compared to Example 1, the preparation raw materials lack one of recombinant collagen and schizophyllan, respectively, and the relative cell proliferation rate is lower than that of Example 1, so it was found that the two components schizophyllan and recombinant collagen work together to have an unexpected synergistic effect in terms of promoting cell proliferation. In Example 5, compared to Example 1, the fermentation medium contains kudzu root powder, and the relative cell proliferation rate is lower than that of Example 1, so it was found that the addition of kudzu root powder reinforces the cell proliferation promoting ability of schizophyllan.
[試験例4]
本試験例は、各実施例または比較例の鎮静・修復効果を有する被覆体の皮膚鎮静・修復について評価した。具体的な評価方法は、以下の通りである。
[Test Example 4]
In this test example, the skin soothing and repair properties of the coverings having soothing and repair effects of each of the Examples and Comparative Examples were evaluated. The specific evaluation method was as follows.
(1)モルモットを66匹取り、雌雄が半分づつであった。試験の1d前に右後足の毛を剃り落とし、脱毛面積が約2cm2であった。モルモットをランダムに11群に分け、各群に6匹のモルモットを含み、それぞれ実施例1~7群、比較例1~3群およびブランクと表記した。 (1) 66 guinea pigs were taken, half of which were male and half of which were female. One day before the test, the hair on the right hind leg was shaved, leaving a hairless area of approximately 2 cm2 . The guinea pigs were randomly divided into 11 groups, each of which contained 6 guinea pigs, and were designated as Example groups 1 to 7, Comparative examples 1 to 3, and blank, respectively.
(2)1日当たり1回で、実施例1~7群、比較例1~3群およびブランクのモルモットに対して、2d連続して、脱毛箇所にそれぞれ実施例または比較例で調製された被覆体溶液を0.05g塗布し、ブランクに対して、等量の脱イオン水を塗布した。 (2) For the guinea pigs in the Example 1-7 groups, the Comparative Example 1-3 groups, and the blank, 0.05 g of the coating solution prepared in each Example or Comparative Example was applied to the hair-removed area once per day for 2 consecutive days, and an equal amount of deionized water was applied to the blank.
(3)試験の3日目、生理食塩水で、それぞれ、0.01%(w/v)、0.02%(w/v)、0.03%(w/v)、0.04%(w/v)、0.05%(w/v)、0.06%(w/v)、0.07%(w/v)、0.08%(w/v)、0.09%(w/v)および0.1%(w/v)のリン酸ヒスタミン溶液を調製した。粗いサンドペーパーで、モルモットの右後足の裏の脱毛箇所を擦傷し、擦傷面積が約1cm2であった。さらに、対応する被覆体溶液を局部に1回塗布し、塗布量が0.05gであった。ブランクに対して、等量の脱イオン水を塗布し、10min後に、擦傷箇所に0.01%(w/v)のリン酸ヒスタミン溶液を0.05mL滴下した。モルモットが3min以内に振り返って右後足を舐めるか否かを観察した。現れなかった場合、継続して擦傷箇所に0.02%(w/v)のリン酸ヒスタミン溶液を0.05mL滴下し、モルモットが3min以内に振り返って右後足を舐めるか否かを観察した。このように、モルモットが3min以内に右後足を舐めったまで、3minおきに上記勾配に応じて濃度を増加し、毎回リン酸ヒスタミン溶液を0.05mL滴下した。この際に滴下したリン酸ヒスタミンの累計総量を痒み閾値(μg)とし、同一群におけるモルモットの痒み閾値の平均値および痒み閾値の差異率を算出し、痒み閾値の差異率=(試験群の痒み閾値-ブランクの痒み閾値)/ブランクの痒み閾値×100%、その結果を表4に示す。 (3) On the third day of the test, 0.01% (w/v), 0.02% (w/v), 0.03% (w/v), 0.04% (w/v), 0.05% (w/v), 0.06% (w/v), 0.07% (w/v), 0.08% (w/v), 0.09% (w/v) and 0.1% (w/v) histamine phosphate solutions were prepared in saline. The depilated area of the right hind paw of the guinea pig was scratched with coarse sandpaper, and the scratch area was about 1 cm2 . In addition, the corresponding coating solution was applied locally once, with an application amount of 0.05 g. For the blank, an equal amount of deionized water was applied, and 10 min later, 0.05 mL of 0.01% (w/v) histamine phosphate solution was dripped onto the scratched area. Observation was performed to see whether the guinea pig turned around and licked its right hind paw within 3 minutes. If not, 0.05 mL of 0.02% (w/v) histamine phosphate solution was continuously dripped onto the scratched area, and observation was performed to see whether the guinea pig turned around and licked its right hind paw within 3 minutes. In this way, the concentration was increased according to the above gradient every 3 minutes, and 0.05 mL of histamine phosphate solution was dripped every time until the guinea pig licked its right hind paw within 3 minutes. The cumulative total amount of histamine phosphate dripped at this time was taken as the itch threshold (μg), and the average value of the itch threshold and the difference rate of the itch threshold of the guinea pig in the same group were calculated, and the difference rate of the itch threshold=(itch threshold of the test group-itch threshold of the blank)/itch threshold of the blank×100%, and the results are shown in Table 4.
表4のデータから分かるように、痒み閾値が高いほど、対応の皮膚バリア作用、即ち、被覆体溶液の鎮静・修復能力が強くなった。実施例4および比較例3は、実施例1に比較すると、前記鎮静・修復効果を有する被覆体の調製原料には、それぞれグリセリンまたは組換えコラーゲンおよびシゾフィランの組合せを欠いて、その痒み閾値の差異率がいずれも実施例1よりも低いことから、グリセリン、組換えコラーゲンおよびシゾフィランの三つものが組み合わせて使用されて、相俟って、皮膚の鎮静・修復の点で予想外の相乗効果を有することが判明した。比較例1および比較例2は、実施例1に比較すると、調製原料には、それぞれ組換えコラーゲンおよびシゾフィランの1種を欠いて、その痒み閾値の差異率がいずれも実施例1よりも低いことから、シゾフィランおよび組換えコラーゲンの2種の成分が相俟って、前記被覆体のかゆみ止め・修復作用を向上させることができることが判明した。実施例5は、実施例1に比較すると、発酵培地には葛根粉末が含まれ、その痒み閾値の差異率が実施例1よりも低いことから、葛根粉末の添加によりシゾフィランの生成物の耐酸化性能を向上させて、皮膚のバリア作用を向上させることができることが判明した。実施例6および実施例7は、実施例1に比較すると、組換えコラーゲンとシゾフィランの質量部の割合が(0.01~0.5):(0.1~5)の範囲ではなく、その痒み閾値の差異率が実施例1よりも低いことから、組換えコラーゲンとシゾフィランの質量部の割合が(0.01~0.5):(0.1~5)の範囲である場合、2種の成分を組み合わせて使用し、皮膚の鎮静・修復機能がより強くなることが判明した。 As can be seen from the data in Table 4, the higher the itch threshold, the stronger the corresponding skin barrier action, i.e., the soothing and repairing ability of the covering solution. In Example 4 and Comparative Example 3, compared to Example 1, the preparation raw materials for the covering having the soothing and repairing effect lacked glycerin or a combination of recombinant collagen and schizophyllan, respectively, and the difference rates of the itch threshold were all lower than those of Example 1, so it was found that the combination of glycerin, recombinant collagen, and schizophyllan had an unexpected synergistic effect in terms of soothing and repairing the skin. In Comparative Example 1 and Comparative Example 2, compared to Example 1, the preparation raw materials lacked one of recombinant collagen and schizophyllan, respectively, and the difference rates of the itch threshold were all lower than those of Example 1, so it was found that the combination of the two components, schizophyllan and recombinant collagen, could improve the anti-itching and repairing action of the covering. In Example 5, compared to Example 1, the fermentation medium contains kudzu root powder, and the difference rate of the itching threshold is lower than that of Example 1, so it was found that the addition of kudzu root powder can improve the oxidation resistance of the schizophyllan product and improve the barrier function of the skin. In Examples 6 and 7, compared to Example 1, the ratio of mass parts of recombinant collagen to schizophyllan is not in the range of (0.01-0.5):(0.1-5), and the difference rate of the itching threshold is lower than that of Example 1, so it was found that when the ratio of mass parts of recombinant collagen to schizophyllan is in the range of (0.01-0.5):(0.1-5), the use of the two components in combination can enhance the soothing and repairing function of the skin.
[試験例5]
実施例で調製された鎮静・修復効果を有する被覆体について安全性評価を行った。具体的な評価方法は以下の通りである。《化粧品安全技術規範2015版》における第7章の人体安全性検出方法中の人体皮膚パッチテスト方法に従って試験を行った。(1)18~60歳の試験要求に満たす女性のボランティアを選択したが、排除標準は、(a)最近1週間に抗ヒスタミン薬を使用したか、または最近1ヶ月以内に免疫抑制剤を使用したもの、(b)最近2ヶ月以内にテスト部位にいずれの抗炎症薬を使用したもの、(c)炎症性皮膚病を罹患した被験者は臨床上で治癒されていないもの、(d)インスリン依存型糖尿
病患者、(e)治療されている喘息または他の慢性呼吸器疾患患者、(f)最近6ヶ月以内に抗癌化学療法を受けたもの、(g)免疫不全または自己免疫疾患患者、(h)哺乳期または妊娠期の女性、(i)両側の乳房を切除した、及び両側の腋下リンパ節を切除したもの、(n)皮膚の被験部位における瘢痕、色素、萎縮、紅斑または他の瑕疵により試験結果に影響されたと判定したもの、(o)ほかの臨床試験研究に参与したもの、(p)体質が極めて敏感なもの、(q)非ボランティアまたは試験要求に従って所定の内容を完成できないものである。(2)各実施例あたり1群に対応し、群ごとにボランティアが10人いて、面積が50mm2超えず、深さが約1mmの合格パッチテスト装置を選用し、各実施例で調製された被覆体溶液をパッチテスト装置のセルに投入し、使用量が約0.025gである。ブランクとして対照ウェルには何も入れない。テストサンプルを添加したパッチテスト装置用の低感作性テープを被験者の背中または前腕側に付け、手のひらで軽く押圧して皮膚に均一に付けさせて、24h維持した。(3)テストサンプルパッチテスト装置を除去した後の30min(圧痕がなくなった後)、24hおよび48hで、表5に示す標準に基づいて皮膚の反応を観察した。表5に示す標準に応じて評価を行った。
[Test Example 5]
The safety evaluation was carried out for the coating with soothing and repairing effects prepared in the examples. The specific evaluation method is as follows. The test was carried out according to the human skin patch test method in the human safety detection method in Chapter 7 of the "Cosmetics Safety Technical Standards 2015 Edition". (1) Female volunteers aged 18-60 years were selected who met the study requirements, with the exclusion criteria being: (a) those who had used antihistamines in the last week or immunosuppressants within the last month; (b) those who had used any anti-inflammatory drugs on the test site within the last two months; (c) subjects with inflammatory skin diseases that were not clinically cured; (d) insulin-dependent diabetes mellitus patients; (e) treated asthma or other chronic respiratory disease patients; (f) those who had undergone anti-cancer chemotherapy within the last six months; (g) immunodeficiency or autoimmune disease patients; (h) lactating or pregnant women; (i) those who had undergone bilateral mastectomy and bilateral axillary lymph node removal; (n) those who judged that the test results would be affected by scarring, pigmentation, atrophy, erythema or other defects on the skin test site; (o) those who had participated in other clinical trial studies; (p) those with extremely sensitive constitutions; and (q) non-volunteers or those who were unable to complete the prescribed content according to the study requirements. (2) Each example corresponds to one group, and there are 10 volunteers in each group. A qualified patch test device with an area not exceeding 50 mm2 and a depth of about 1 mm is selected, and the coating solution prepared in each example is put into the cell of the patch test device, and the amount used is about 0.025 g. Nothing is put into the control well as a blank. The low sensitizing tape for the patch test device containing the test sample is attached to the back or forearm of the subject, and is lightly pressed with the palm of the hand to make it evenly attached to the skin, and is maintained for 24 hours. (3) After removing the test sample patch test device, the skin reaction is observed 30 minutes (after the indentation disappears), 24 hours and 48 hours according to the standards shown in Table 5. Evaluation is performed according to the standards shown in Table 5.
結果から分かるように、本発明で調製された製品は、安全で、刺激がなく、より高い使用価値を有した。 As can be seen from the results, the product prepared according to the present invention was safe, non-irritating, and had higher usage value.
本発明は上記実施例によって本発明の調製プロセスを説明したが、本発明は上記実施例に限られるものではない、即ち、本発明は上記実施例によって実施しなければならないものではないと出願人は声明する。当業者にとって、本発明に対する如何なる改良、本発明の製品の各原料への等価置換及び補助成分の追加、具体的な実施形態の選択等はいずれも本発明の保護範囲及び開示範囲に入ることが明瞭である。 The present invention describes the preparation process of the present invention through the above examples, but the applicant declares that the present invention is not limited to the above examples, that is, the present invention does not have to be carried out according to the above examples. It is clear to those skilled in the art that any improvements to the present invention, equivalent replacement of each raw material of the product of the present invention, addition of auxiliary ingredients, selection of specific embodiments, etc., are all within the protection scope and disclosure scope of the present invention.
以上、本発明の好適な実施形態を詳しく説明したが、本発明は、上記実施形態における具体的なディテールに限定されない。本発明の技術的構想範囲内で、本発明の技術案に対して複数種の簡単な変形を行うことができ、これらの簡単な変形は、いずれも本発明の保
護範囲に属するものである。
Although the preferred embodiments of the present invention have been described in detail above, the present invention is not limited to the specific details of the above embodiments. Within the technical concept of the present invention, a number of simple modifications can be made to the technical solution of the present invention, and all of these simple modifications fall within the protection scope of the present invention.
なお、上記の具体的な実施形態に記載された各具体的な技術的特徴は、矛盾しない場合、任意の適切な形態で組み合わせることができる。不必要な繰り返しを回避するために、本発明では、別途に各種の可能な組合せ形態について説明しない。 The specific technical features described in the above specific embodiments can be combined in any suitable manner if not contradictory. In order to avoid unnecessary repetition, the present invention does not separately describe various possible combination forms.
Claims (15)
前記皮膚の鎮静・修復用の組換えコラーゲンをコードするヌクレオチド配列は、SEQ
ID NO:1で示される配列である、
ことを特徴とする鎮静・修復効果を有する組成物。 Recombinant collagen for skin soothing and repair; and schizophyllan.
The nucleotide sequence encoding the recombinant collagen for skin soothing and repair is SEQ ID NO:
The sequence shown in ID NO: 1
A composition having a soothing and restorative effect.
0.01~0.5部の皮膚の鎮静・修復用の組換えコラーゲンと、0.1~5部のシゾフィランと、を含む、
ことを特徴とする請求項1に記載の鎮静・修復効果を有する組成物。 The composition having a soothing and repairing effect comprises, by weight, 0.01 to 0.5 parts of recombinant collagen for soothing and repairing the skin, and 0.1 to 5 parts of schizophyllan.
A composition having a soothing and restorative effect according to claim 1 .
ことを特徴とする請求項1に記載の鎮静・修復効果を有する組成物。 The soothing and restorative composition further comprises a moisturizer.
A composition having a soothing and restorative effect according to claim 1 .
ことを特徴とする請求項3に記載の鎮静・修復効果を有する組成物。 The moisturizing agent includes any one or a combination of at least two of glycerin, 1,3-butanediol, sodium hyaluronate, sodium acetylated hyaluronate, hydrolyzed sodium hyaluronate, or ceramide 3.
A composition having a soothing and restorative effect according to claim 3 .
ことを特徴とする請求項4に記載の鎮静・修復効果を有する組成物。 The moisturizer is glycerin.
A composition having a soothing and restorative effect as claimed in claim 4 .
0.01~0.5部の皮膚の鎮静・修復用の組換えコラーゲン、0.1~5部のシゾフィラン、および5~50部のグリセリンを含む、
ことを特徴とする請求項1に記載の鎮静・修復効果を有する組成物。 The soothing and restorative composition comprises, in parts by weight:
A skin soothing and repairing composition, comprising 0.01 to 0.5 parts of recombinant collagen, 0.1 to 5 parts of schizophyllan, and 5 to 50 parts of glycerin.
A composition having a soothing and restorative effect according to claim 1 .
葛根を含有する培地でスエヒロタケを発酵培養させ、発酵培養液に対してSevag法でタンパク質を除去した後、エタノール溶液を添加して発酵培養液における多糖を沈殿させ、遠心して前記シゾフィランを調製したことを含む、
ことを特徴とする請求項1に記載の鎮静・修復効果を有する組成物。 The method for preparing schizophyllan comprises the steps of:
The method includes fermenting Schizophyllum commune in a medium containing kudzu root, removing proteins from the fermentation culture liquid by the Sevag method, adding an ethanol solution to precipitate polysaccharides in the fermentation culture liquid, and centrifuging the mixture to prepare the schizophyllan.
A composition having a soothing and restorative effect according to claim 1 .
ことを特徴とする鎮静・修復効果を有する被覆体。 A composition having a soothing and restorative effect according to any one of claims 1 to 7 , comprising a microcapsule material and the composition is coated on the inside of the microcapsule material.
A coating having a soothing and restorative effect.
ことを特徴とする請求項8に記載の鎮静・修復効果を有する被覆体。 The preparation raw material of the microencapsulation material includes a polyglyceryl nonionic surfactant;
9. The soothing and restorative covering according to claim 8 .
ことを特徴とする請求項9に記載の鎮静・修復効果を有する被覆体。 The polyglyceryl nonionic surfactant includes any one or a combination of at least two of polyglycerin-10 diisostearate, polyglycerin-10 laurate, or polyglycerin-10 oleate.
10. The soothing and restorative covering according to claim 9 .
ステップ(1)で調製された混合物に対して被覆支援処理を行い、前記鎮静・修復効果を有する被覆体を調製し、前記被覆支援処理は、高電圧パルス電界支援処理および/または超音波支援処理を含む、ステップ(2)と、を含む、
ことを特徴とする請求項8に記載の鎮静・修復効果を有する被覆体の調製方法。 (1) mixing a polyglyceryl nonionic surfactant with a soothing and restorative composition according to any one of claims 1 to 7 ;
Step (2) of subjecting the mixture prepared in step (1) to a coating-assisted treatment to prepare the coating having the soothing and repairing effect, the coating-assisted treatment including a high-voltage pulsed electric field-assisted treatment and/or an ultrasonic-assisted treatment;
9. A method for preparing a coating having a soothing and restorative effect according to claim 8 .
ことを特徴とする請求項11に記載の鎮静・修復効果を有する被覆体の調製方法。 The coating assisted process according to step (2) is a high voltage pulse electric field assisted process;
A method for preparing a coating having a soothing and restorative effect according to claim 11 .
ことを特徴とする請求項11に記載の鎮静・修復効果を有する被覆体の調製方法。 The high voltage pulse electric field assisted treatment has an electric field strength of 0.5-2 kV/cm, a pulse treatment number of 10-60, and a material conductivity of 2000-6000 μS/cm;
A method for preparing a coating having a soothing and restorative effect according to claim 11 .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310123476.3A CN116003577B (en) | 2023-02-14 | 2023-02-14 | Recombinant collagen for skin soothing and repairing and application thereof |
CN202310123476.3 | 2023-02-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2024115499A JP2024115499A (en) | 2024-08-26 |
JP7601957B2 true JP7601957B2 (en) | 2024-12-17 |
Family
ID=86030055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023108556A Active JP7601957B2 (en) | 2023-02-14 | 2023-06-30 | Recombinant collagen for skin soothing and repair and uses thereof |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7601957B2 (en) |
CN (1) | CN116003577B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117481996B (en) * | 2023-11-29 | 2024-06-18 | 广东丸美生物技术股份有限公司 | Mild anti-aging composition containing recombinant collagen and application thereof |
CN117598926A (en) * | 2023-11-29 | 2024-02-27 | 广东丸美生物技术股份有限公司 | A skin barrier repair composition containing recombinant collagen and its application |
CN117503658B (en) * | 2023-12-05 | 2024-06-18 | 广东丸美生物技术股份有限公司 | Multi-effect composition containing recombinant collagen and preparation method and application thereof |
CN117815440A (en) * | 2023-12-29 | 2024-04-05 | 广东丸美生物技术股份有限公司 | Repairing, anti-inflammatory and moisturizing composition containing recombinant collagen and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003277399A (en) | 2002-03-15 | 2003-10-02 | Lg Household & Health Care Ltd | Fused peptide of peptide derived from c-terminus of human collagen type i to which tat peptide is linked, method of producing the same and skin wrinkle-improving cosmetic composition containing the same |
CN103102407A (en) | 2013-01-29 | 2013-05-15 | 西安益力欣生物科技有限公司 | Genetic recombinant human-like collagen |
CN111363029A (en) | 2018-12-25 | 2020-07-03 | 江苏江山聚源生物技术有限公司 | Recombinant human III-type collagen, expression strain and construction method thereof |
CN111944057A (en) | 2020-07-23 | 2020-11-17 | 广州启妆生物科技有限公司 | Recombinant human collagen peptide and application thereof |
CN113880941A (en) | 2020-07-03 | 2022-01-04 | 江苏江山聚源生物技术有限公司 | Recombinant human IxIII collagen, expression strain and application thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391288B1 (en) * | 1999-07-27 | 2002-05-21 | Shiseido Co., Ltd. | Microcapsule and method of making the same |
CN101559041B (en) * | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | Polypeptide drug sustained-release microsphere or microcapsule preparation with uniform particle size and preparation method |
CN102755272B (en) * | 2012-07-20 | 2013-09-25 | 澳宝化妆品(惠州)有限公司 | Multi-effect moisturizing and softening composition |
CN103932969A (en) * | 2014-04-16 | 2014-07-23 | 法国奢蔻化妆品有限公司 | Deep-sea fish skin collagen peptide anti-aging firming bright moisturizing cosmetics and preparation method |
CN104161715A (en) * | 2014-06-26 | 2014-11-26 | 吴雪琴 | Preparation method and product of whitening skin care emulsion |
CN105963257B (en) * | 2016-04-26 | 2021-01-22 | 广州帝奇医药技术有限公司 | Preparation method of sustained-release particles |
CN109481326A (en) * | 2018-11-19 | 2019-03-19 | 珠海伊斯佳科技股份有限公司 | A kind of after-sun recovery Essence |
CN112370489A (en) * | 2020-11-21 | 2021-02-19 | 陕西远志医药生物工程有限公司 | Antibacterial gel for restoring ecological balance of women and preparation method thereof |
CN112842944A (en) * | 2021-03-19 | 2021-05-28 | 唐发彬 | Cosmetic based on anti-aging collagen |
CN114288389A (en) * | 2021-12-07 | 2022-04-08 | 尚诚怡美(成都)生物科技有限公司 | A kind of anti-enzymatic collagen complex and its application |
CN114404307B (en) * | 2021-12-17 | 2022-10-14 | 广东丸美生物技术股份有限公司 | Arginine/lysine polypeptide microcapsule inclusion and preparation method and application thereof |
CN114306125B (en) * | 2021-12-27 | 2023-01-13 | 广东丸美生物技术股份有限公司 | Composition containing schizophyllan with different molecular weights as well as preparation method and application thereof |
CN114652636B (en) * | 2022-03-10 | 2023-11-17 | 广东丸美生物技术股份有限公司 | Anti-wrinkle repair composition, preparation method thereof and cosmetic containing composition |
CN115006322B (en) * | 2022-06-06 | 2023-09-19 | 广东丸美生物技术股份有限公司 | Formula and preparation method of multifunctional eye mask with instant and long-acting effects |
-
2023
- 2023-02-14 CN CN202310123476.3A patent/CN116003577B/en active Active
- 2023-06-30 JP JP2023108556A patent/JP7601957B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003277399A (en) | 2002-03-15 | 2003-10-02 | Lg Household & Health Care Ltd | Fused peptide of peptide derived from c-terminus of human collagen type i to which tat peptide is linked, method of producing the same and skin wrinkle-improving cosmetic composition containing the same |
CN103102407A (en) | 2013-01-29 | 2013-05-15 | 西安益力欣生物科技有限公司 | Genetic recombinant human-like collagen |
CN111363029A (en) | 2018-12-25 | 2020-07-03 | 江苏江山聚源生物技术有限公司 | Recombinant human III-type collagen, expression strain and construction method thereof |
CN113880941A (en) | 2020-07-03 | 2022-01-04 | 江苏江山聚源生物技术有限公司 | Recombinant human IxIII collagen, expression strain and application thereof |
CN111944057A (en) | 2020-07-23 | 2020-11-17 | 广州启妆生物科技有限公司 | Recombinant human collagen peptide and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2024115499A (en) | 2024-08-26 |
CN116003577A (en) | 2023-04-25 |
CN116003577B (en) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7601957B2 (en) | Recombinant collagen for skin soothing and repair and uses thereof | |
CN113855603B (en) | Combined fermentation product, skin external preparation containing same, and preparation method and application of combined fermentation product | |
CN116850128B (en) | A microecological regulation composition, preparation method and application | |
CN110917120A (en) | Sticky antibacterial repairing material and preparation method and application thereof | |
CN113855597A (en) | Antioxidant, anti-inflammatory and soothing repair composition, preparation method and application thereof | |
CN113855609A (en) | Glutinous rice fermented extract and anti-eczema application thereof | |
CN111420023B (en) | Complex containing type I collagen and hyaluronic acid, preparation and application | |
CN109381348B (en) | Stable transparent toning lotion with high collagen content | |
CN115869207A (en) | A composition based on tuna collagen peptide and its application in cosmetics | |
JP3435181B2 (en) | External preparation for melanin production suppression | |
CN110368347A (en) | Anti-ageing reparation double-layer bi-color essence of one kind and preparation method thereof | |
CN117598926A (en) | A skin barrier repair composition containing recombinant collagen and its application | |
CN118286104A (en) | Sustained-release whitening composition and preparation method and application thereof | |
CN113995775B (en) | A kind of probiotic foot mask with foot protection effect and preparation method thereof | |
KR102381645B1 (en) | Cosmetic Composition Comprising Poria cocos Fermentation Extract | |
CN106581741A (en) | Reconstructed human source collagen paste and preparation method thereof | |
CN113230154B (en) | Composition with anti-allergy, relieving and anti-inflammation effects and preparation method and application thereof | |
CN115054566B (en) | Scalp aging resisting composition and preparation method thereof | |
CN116172893A (en) | Anti-aging composition and application thereof | |
CN114681386A (en) | Animal-derived exosome composition and application thereof in preparation of anti-aging and anti-allergic skin preparation | |
CN116396376B (en) | Elastin-like polypeptide for improving tissue elasticity and tensile capacity and application thereof | |
CN112675068A (en) | Preparation method of face cream of autologous adipose-derived stem cell cytokine extracting solution | |
CN118415931B (en) | Antibacterial skin-tightening Qilan agilawood shower gel and preparation method and application thereof | |
CN117815102B (en) | Composition containing recombinant collagen and preparation method and application thereof | |
CN117257713B (en) | Rice ferment containing lactobacillus and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240416 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240903 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7601957 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |